MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-17-2026
Longeveron Revenue 2011-2026 | LGVN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Longeveron
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.2 M | 2.39 M | 709 K | 1.22 M | 1.31 M | 5.63 M | 5.64 M | 2.13 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.64 M | 709 K | 2.53 M |
Quarterly Revenue Longeveron
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 137 K | 316 K | 381 K | 773 K | 468 K | 548 K | 150 K | 217 K | 279 K | - | 265 K | 466 K | 370 K | - | 232 K | 489 K | 376 K | - | 1.86 M | 876 K | 1.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.86 M | 137 K | 551 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.8 | 5.33 % | $ 9.14 B |  Australia |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
66.4 M | $ 2.63 | -1.22 % | $ 16.5 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
482 M | $ 88.34 | -3.22 % | $ 27.2 B | Germany |
 |
Alnylam Pharmaceuticals
ALNY
|
3.71 B | $ 316.2 | -4.28 % | $ 41.4 B | USA |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
330 M | $ 4.44 | -0.67 % | $ 730 M | Britain |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
argenx SE
ARGX
|
36.4 M | $ 743.15 | -0.68 % | $ 25 B |  Niderland |
 |
Завод ДИОД
DIOD
|
517 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
372 M | - | - | - | Russia |
 |
Aptorum Group Limited
APM
|
912 K | $ 0.89 | - | $ 4.85 M | China |
 |
Applied Therapeutics
APLT
|
9.99 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Teligent, Inc.
TLGT
|
45.3 M | - | -13.85 % | $ 16.1 M | USA |
 |
Cerus Corporation
CERS
|
234 M | $ 1.8 | -2.7 % | $ 343 M | USA |
 |
AbbVie
ABBV
|
16.6 B | $ 202.28 | -2.11 % | $ 358 B | USA |
 |
Aquestive Therapeutics
AQST
|
44.5 M | $ 4.04 | -1.28 % | $ 432 M | USA |
 |
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | USA |
 |
Viela Bio, Inc.
VIE
|
11.7 M | - | - | $ 2.91 B | USA |
 |
Coherus BioSciences
CHRS
|
42.2 M | $ 1.63 | -2.69 % | $ 191 M | USA |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 3.32 | -2.06 % | $ 992 M | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
82 M | $ 8.12 | -1.22 % | $ 222 M |  Israel |
 |
Ardelyx
ARDX
|
407 M | $ 5.8 | -2.93 % | $ 1.4 B | USA |